LL-37, human TFA|西域试剂

LL-37, human TFA,99.61%

产品编号：Bellancom-P1222A| 分子式：C₂₀₅H₃₄₀N₆₀O₅₃.C₂HF₃O₂| 分子量：4607.28

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-P1222A	￥1250.00	杭州北京（现货）
Bellancom-P1222A	￥2600.00	杭州北京（现货）
Bellancom-P1222A	￥4100.00	杭州北京（现货）
Bellancom-P1222A	￥8200.00	杭州北京（现货）
Bellancom-P1222A	￥13200.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

LL-37, human TFA

产品介绍

LL-37, human TFA 是一种具有 37 个残基的两亲性组织蛋白酶衍生的抗菌肽，具有广泛的抗菌活性。LL-37, human TFA 有助于保护角膜免受感染，调节伤口愈合。

生物活性

LL-37, human TFA is a 37-residue, amphipathic, cathelicidin-derived antimicrobial peptide, which exhibits a broad spectrum of antimicrobial activity. LL-37, human TFA could help protect the cornea from infection and modulates wound healing.

体外研究

LL-37, human TFA (1-20 μg/mL; 24 h) affects HCECs migration.
LL-37, human TFA (0.0001-5 μg/mL; 6-24 h) affects cytokine secretion in HCECs.
LL-37, human TFA (1-100 μg/mL; 24 h) shows dose-dependently cytotoxic to HCECs at concentrations over 10 μg/mL.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Migration Assay

Cell Line:	Human corneal epithelial cell (HCEC)
Concentration:	1, 2.5, 5, 10 and 20 μg/mL
Incubation Time:	24 hours
Result:	Dose-dependently stimulated HCECs migration but showed no effect on cells proliferation.

Cell Viability Assay

Cell Line:	Human corneal epithelial cell (HCEC)
Concentration:	0.0001, 0.001, 0.01, 0.1, 0.5, 1, and 5 μg/mL
Incubation Time:	6 and 24 hours
Result:	Dose-dependently increased IL-8, IL-6, IL-1β and TNF-α secretion at 6 and 24 hours in HCECs.

体内研究
(In Vivo)

LL-37, human TFA (0.4-2.0 mg/kg; intratracheal injection once) ameliorates MRSA-induced pneumonia of mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	6-8 week-old C57BL/6 mice with MRSA-induced pneumonia
Dosage:	0.4, 0.8, 1.2, 1.6 and 2.0 mg/kg
Administration:	Intratracheal injection; 0.4-2.0 mg/kg once
Result:	Decreased IL-6 and TNF-α release to attenuated MRSA-induced pneumonia of testing mice.

体内研究

LL-37, human TFA (0.4-2.0 mg/kg; intratracheal injection once) ameliorates MRSA-induced pneumonia of mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	6-8 week-old C57BL/6 mice with MRSA-induced pneumonia
Dosage:	0.4, 0.8, 1.2, 1.6 and 2.0 mg/kg
Administration:	Intratracheal injection; 0.4-2.0 mg/kg once
Result:	Decreased IL-6 and TNF-α release to attenuated MRSA-induced pneumonia of testing mice.

体内研究

LL-37, human TFA (0.4-2.0 mg/kg; intratracheal injection once) ameliorates MRSA-induced pneumonia of mice.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	6-8 week-old C57BL/6 mice with MRSA-induced pneumonia
Dosage:	0.4, 0.8, 1.2, 1.6 and 2.0 mg/kg
Administration:	Intratracheal injection; 0.4-2.0 mg/kg once
Result:	Decreased IL-6 and TNF-α release to attenuated MRSA-induced pneumonia of testing mice.

性状

Solid

溶解性数据

In Vitro:

H₂O : 100 mg/mL (21.70 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	0.2170 mL	1.0852 mL	2.1705 mL
5 mM	0.0434 mL	0.2170 mL	0.4341 mL
10 mM	0.0217 mL	0.1085 mL	0.2170 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶